The lncRNA 44s2 Study Applicability to the Design of 45-55 Exon Skipping Therapeutic Strategy for DMD

• Published in: Biomedicines 2021-02, Vol.9 (2), p.219
• Main Authors: Gargaun, Elena, Falcone, Sestina, Solé, Guilhem, Durigneux, Julien, Urtizberea, Andoni, Cuisset, Jean Marie, Benkhelifa-Ziyyat, Sofia, Julien, Laura, Boland, Anne, Sandron, Florian, Meyer, Vincent, Deleuze, Jean François, Salgado, David, Desvignes, Jean-Pierre, Béroud, Christophe, Chessel, Anatole, Blesius, Alexia, Krahn, Martin, Levy, Nicolas, Leturcq, France, Pietri-Rouxel, France
• Format: Article
• Language: English
• Subjects: Age; Becker muscular dystrophy (BMD); Becker's muscular dystrophy; Binding sites; Biomarkers; Biopsy; Cardiomyopathy; Cell cycle; CRISPR; Deoxyribonucleic acid; DNA; Duchenne muscular dystrophy (DMD); Dystrophin; Exon skipping; Genotype & phenotype; Human health and pathology; Introns; Kinases; Life Sciences; lncRNA; long noncoding RNA; Musculoskeletal system; Mutation; Myoblasts; Myocytes; Myogenesis; ncRNA; Patients; Phenotypes; Proteins; Skeletal muscle
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines9020219

In skeletal muscle, long noncoding RNAs (lncRNAs) are involved in dystrophin protein stabilization but also in the regulation of myocytes proliferation and differentiation. Hence, they could represent promising therapeutic targets and/or biomarkers for Duchenne and Becker muscular dystrophy (DMD/BMD). DMD and BMD are X-linked myopathies characterized by a progressive muscular dystrophy with or without dilatative cardiomyopathy. Two-thirds of gene mutations are represented by deletions, and 63% of patients carrying deletions are eligible for 45 to 55 multi-exons skipping (MES), becoming BMD patients (BMDΔ45-55). We analyzed the genomic lncRNA presence in 38 BMDΔ45-55 patients and characterized the lncRNA localized in introns 44 and 55 of the gene. We highlighted that all four lncRNA are differentially expressed during myogenesis in immortalized and primary human myoblasts. In addition, the lncRNA44s2 was pointed out as a possible accelerator of differentiation. Interestingly, lncRNA44s expression was associated with a favorable clinical phenotype. These findings suggest that lncRNA44s2 could be involved in muscle differentiation process and become a potential disease progression biomarker. Based on these results, we support MES45-55 therapy and propose that the design of the CRISPR/Cas9 MES45-55 assay consider the lncRNA sequences bordering the exonic 45 to 55 deletion.